Weill Cornell Medical College

Ajax Therapeutics, Inc. is going after an old target in myelofibrosis and other myeloproliferative neoplasms (MPNs) in a new way with its type II JAK2 inhibitor, AJ1-11095, which it will take into th

Lexeo Therapeutics has accomplished a lot in the nine months since it launched with $85m in series A venture capital for development of AAV-mediated gene therapies that treat rare and prevalent monog

Below is Scrip’s regular roundup, including information from Strategic Transactions , of recent technology transfer agreements and collaborations between companies and academic or other research inst

The largest start-up venture capital financing in the first quarter was completed by Anthos Therapeutics Inc. with a $250m Series A round, but Series B rounds made up the largest segment of the $3.4